Drug Trial Radar · NCT06919991
Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
May 2, 2025
Primary completion
Oct 18, 2025
Study completion Oct 18, 2025
Sponsor
- Lead sponsor
- Arcus Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the effects of multiple doses of itraconazole (a strong CYP3A4 inhibitor) on single dose PK of casdatifan in healthy adults and to assess the effects of multiple doses of phenytoin (a strong CYP3A4 inducer) on single dose PK of casdatifan in healthy adults.
Conditions
- Healthy Participants
Interventions
CasdatifanDrug
Administered as a single dose in treatment Periods 1, 2, and 3
ItraconazoleDrug
Administered as multiple doses in treatment Period 2
PhenytoinDrug
Administered as multiple doses in treatment Period 3
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Plasma Drug Concentration-Time Curve (AUC) for casdatifanTime frame: Up to 168 hours post dose for Period 1; up to 216 hours post dose for Period 2; and up to 120 hours post dose for Period 3
- Maximum Concentration (Cmax) in Plasma for casdatifanTime frame: Up to 168 hours post dose for Period 1; up to 216 hours post dose for Period 2; and up to 120 hours post dose for Period 3
- Time to Maximum Concentration (Tmax) in Plasma for casdatifanTime frame: Up to 168 hours post dose for Period 1; up to 216 hours post dose for Period 2; and up to 120 hours post dose for Period 3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.